Search Protocols under revision. Back New search Go to resultsDiseaseMain groupCross-Sectional, Transplantation, Cellular TherapySolid TumorsProtocol groupGastroenterologic OncologyGynecological OncologyradiotherapyThoracic TumorsTumor, regardless of entityDiseaseBreast CancerLung Carcinoma, Non-Small CellLung Carcinoma, Small CellMerkel Cell CarcinomaTumor, Various OrgansSubgroupPD-L1+ICD10C34.-C44.9C50.-MeSHCarcinoma, Merkel CellSmall Cell Lung CarcinomaSequenceASTRUM-005: SERP4.5/CRBP5/ETOP100, SCLC, C1-4 (PID2922) -|- SERP4.5, C5+ (PID2923)CASPIAN: DURV1500/CISP80/ETOP100, SCLC (PID1734) -|- DURV1500 maint. (PID1594)CASPIAN: DURV1500/CRBP5/ETOP100, SCLC (PID1593) -|- DURV1500 maint. (PID1594)CISP80/ETOP100/Radiation, SCLC, A (PID266) -|- IRIN60/CISP60, B (PID267)DeLLphi-301: TARL(1/10), SCLC, C1 (PID2858) -|- TARL10, C2+ (PID2859)DOXO40/LURB2, SCLC (PID2628) -|- LURB3.2, maint. (PID2629)IMpower133: ATEZ1200/CRBP5/ETOP100, SCLC (PID1341) -|- ATEZ1200, maint. (PID1342)KEYNOTE-604: PEMB200/CISP75/ETOP100, SCLC (PID610) -|- PEMB200, maint. (PID631)KEYNOTE-604: PEMB200/CRBP5/ETOP100, SCLC (PID630) -|- PEMB200, maint. (PID631)RATIONALE-312ChemotherapyChemo-substanceAtezolizumabCarboplatinCisplatinCyclophosphamideDoxorubicinDurvalumabEpirubicinEtoposideHydrocortisoneIfosfamideIrinotecanLurbinectedinPaclitaxelPembrolizumabSerplulimabTarlatamabThiotepaTislelizumabTopotecanVincristineChemo-substanceAtezolizumabCarboplatinCisplatinCyclophosphamideDoxorubicinDurvalumabEpirubicinEtoposideHydrocortisoneIfosfamideIrinotecanLurbinectedinPaclitaxelPembrolizumabSerplulimabTarlatamabThiotepaTislelizumabTopotecanVincristineChemo-substanceAtezolizumabCarboplatinCisplatinCyclophosphamideDoxorubicinDurvalumabEpirubicinEtoposideHydrocortisoneIfosfamideIrinotecanLurbinectedinPaclitaxelPembrolizumabSerplulimabTarlatamabThiotepaTislelizumabTopotecanVincristineChemo-substanceAtezolizumabCarboplatinCisplatinCyclophosphamideDoxorubicinDurvalumabEpirubicinEtoposideHydrocortisoneIfosfamideIrinotecanLurbinectedinPaclitaxelPembrolizumabSerplulimabTarlatamabThiotepaTislelizumabTopotecanVincristineNo. Substances1234 RadiotherapySupportive therapySupportive substanceBalanced Crystalloid SolutionCimetidineDexamethasoneDimetindenFosaprepitantGranisetronMagnesiumMagnesium sulfateMesnaNaCl 0.9%PegfilgrastimPotassium chlorideSupportive substanceBalanced Crystalloid SolutionCimetidineDexamethasoneDimetindenFosaprepitantGranisetronMagnesiumMagnesium sulfateMesnaNaCl 0.9%PegfilgrastimPotassium chlorideSupportive substanceBalanced Crystalloid SolutionCimetidineDexamethasoneDimetindenFosaprepitantGranisetronMagnesiumMagnesium sulfateMesnaNaCl 0.9%PegfilgrastimPotassium chlorideSupportive substanceBalanced Crystalloid SolutionCimetidineDexamethasoneDimetindenFosaprepitantGranisetronMagnesiumMagnesium sulfateMesnaNaCl 0.9%PegfilgrastimPotassium chlorideNo. Substances1234567810Protocol classificationTherapy classificationalternativecurrent standardIntensityStandard doseTherapy indicationFirst lineRelapse therapySecond lineseveral possibleThird line Therapy phaseConsolidationInductionMaintenanceTherapy intentioncurativecurative or palliativepalliativeRisksAlopeciaAnemia Hb below 8g/dlAnemia Hb below 10g/dlAnorexiaAstheniaCardiotoxicityConstipationCystitisCytokine Release SyndromeDiarrheaDyspneaElectrolyte DisturbanceEmbolismEmetogenicityEmetogenicity (MASCC/ESMO)EsophagitisFatigueFebrile NeutropeniaHepatotoxicityHyperglycemiaHypertensionHyperthyroidismHypoalbuminemiaHypokalemiaHyponatremiaHypothyroidismIncrease AminotransferasesLeukopeniaMyalgiasNephrotoxicityNeuropathyNeurotoxicityNeutropeniaOral MucositisPneumoniaPneumonitisPruritusRashSepsisThrombocytopenia below 50 000/µlUpper Respiratory Tract Infection only studiesPublicationAuthorAhn MJAisner JAix SBleehen, NCheng YEckardt JRFaivre-Finn CGatzemeier UGoto KHanna, NHanna NHong WKHorn LIhde, DJohnson DHLoehrer PJMaisch BMartinoni A Mavroudis DNeubauer MNiederle NNoda, KNoda KOkamoto HOtt PPawel JPaz-Ares LPujol JL et al.Quoix, EReck MRudin CSaito HSchiller JSchmittel, ASchmittel ASeifart UShah CSkarlos DVSmith, IESpigel DSundstrøm STakada MThatcher NTrigo JTurrisi ATYamamoto NDiseaseExtensive-Stage SCLC, Erstlinie, ECOG 0-1Extensive-Stage Small-Cell Lung CancerExtensive disease small cell lung cancerFortgeschrittenes kleinzelliges Lungenkarzinom (M1), Karnofsky-Index von 70% oder mehrfortgeschrittenes oder metastasiertes kleinzelliges Lungenkarzinom, Erstlinie, ECOG 0-2Kleinzelliges Lungenkarzinomkleinzelliges Lungenkarzinom, limited disease, ECOG 0-2Kleinzelliges Lungenkarzinom, limited und extensive disease, Erstlinie, ECOG 0-2kleinzelliges Lungenkarzinom, Stadium IV, Erstlinie, ECOG 0-1kleinzelliges Lungenkarzinom Stadium I-IIIB, Erstlinie, ECOG 0-2kleinzelliges Lungenkarzinom Stadium IV, Erstlinie, ECOG 0-2Maligner Perikarderguss, hämodynamisch relevantNSCLC, limited und extensive disease, Zweitlinie, Progress nach Erstlinie mind. 60 Tage nach ErstlinienkomplettierungSCLC, cT3/4 ohne Möglichkeit zur Radiatio oder extensive disease, ECOG 0-1SCLC, Drittlinie, ECOG 0-1SCLC, Erstlinientherapie bei Extensive-DiseaseSCLC, Erstlinientherapie bei Extensive-Disease SCLC, Erstlinientherapie bei extensive diseaseSCLC, Erstlinientherapie bei extensive disease SCLC, extensive disease, >70 Jahre und ECOG 0-2 oder < 70 Jahre und ECOG 3SCLC, extensive disease, Erstlinie, ECOG 0-1SCLC, extensive disease, Erstlinie, Patienten > 70 Jahre und ECOG 0-2 oder < 70 Jahre und ECOG 2SCLC, inoperabel, limited u extensive disease, männlichSCLC, LD und ED, komplette oder Teilremission nach Erstlinie, Therapiepause > 90 Tage, ECOG 0-2SCLC, limited diseaseSCLC, limited disease, ECOG 0-2SCLC, limited disease, ECOG: 0-2, CONVERT TrialSCLC, limited disease, kein Progress nach Radiochemotherapie, ECOG 0-1SCLC, limited disease, Stadium II-IVSCLC, limited disease exclusive Stadium ISCLC, limited disease ohne Möglichkeit zur Radiatio, extensive disease, Patienten älter als 70 Jahre, ECOG 0-2SCLC, limited und extended diseaseSCLC, limited und extended disease, ECOG 0-2, chemo-naivSCLC, limited und extensive diseaseSCLC, Progress > 90 Tage nach Ansprechen und Komplettierung der Erstlinie, ECOG 0-2SCLC, therapierefraktär oder rezidivierend, ECOG 0-2SCLC, therapierefraktär oder rezidivierend, mind. eine VortherapieSCLC, Zweitlinie, ECOG 0-2SCLC, Zweitlinie nach platinbasierter Therapie, ECOG 0-2SCLC, Zweitlinie nach platinbasierter Therapie ECOG 0-2SCLC, Zweitlinie nach Platinkombination oder TKI, PD-L1 Expression > 1%, ECOG 0-1SCLC extensive disease, chemo-naiv, ECOG 0-2SCLC limited u extensive diseaseSCLC limited u extensive disease, unbehandeltSCLC limited und extensive diseaseZweitlinientherapie des sensitiven kleinzelligen Lungenkarzinom, <75 Jahre, ECOG 0-2OriginAbteilung für thorakale Onkologie, Krankenhaus Grosshansdorf, Universität Hamburg, DeutschlandArbeitsgemeinschaft Internistische OnkologieAthens Medical Center, GreeceBarnard Cancer Center, Washington University School of MedicineBenjamin Franklin Campus Berlin, St. Marien Hospital Amberg, Universitätsmedizin Mainz, Westpfalzklinikum KaiserslauternBristol Lung Cancer Study GroupBritish Medical Research Council LU21 StudieCardiology Unit, Milan, ItalyCenter for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, KEYNOTE-028Department of Internal Medicine-Cardiology, Philipps University, Marburg, GermanyDepartment of Medical Oncology, Hospital Universitario 12 de Octubre, Madrid, Spain, ATLANTISDepartment of Medical Oncology, University of Crete, GriechenlandDepartment of Medicine, SUNY Upstate Medical University, Syracuse, USADepartment of Oncology, University Hospital of TrondheimDepartment of Thoracic Oncology, National Cancer Center Hospital East, Chiba, JapanDivision of Medical Oncology, Vanderbilt University Medical CenterDivision of Molecular and Clinical Cancer Sciences, University of Manchester, UKDivision of Molecular and Clinical Cancer Sciences, University of Manchester, UK, CONVERT studyEastern Cooperative Onkology GroupFrench Federation of Cancer InstitutesGreek Lung Cancer Cooperative GroupHamm-Kliniken, Marburg, DeutschlandHanna N, Indiana University, Hoosier Oncology GroupHoosier Oncology GroupHospital Universitario Virgen de la Victoria, Malaga, SpainJapan Clinical Oncology GroupJapan Clinical Oncology Group, Studie 9104Japan Clinical Oncology Group 9702Jilin Cancer Hospital, Changchun, China, ASTRUM-005 trialJilin Cancer Hospital, Changchun, People's Republic of China, RATIONALE-312 trialKansas City Cancer Center, US Oncology Research Inc.Lung Unit, Royal Marsden Hospital, Sutton, EnglandMedical Research Council Lung Cancer Working PartyMedical University of South Carolina, Charleston, USAMemorial Sloan Kettering Cancer Center, New York, NY, Keynote-604Peking University Cancer Hospital and Institute, Beijing, ADRIATIC trialPulmonology Unit, University Hospital Strasbourg, FrankreichSarah Cannon Research Institute, Nashville, TN, SALUTE trialSungkyunkwan University School of Medicine, Seoul, South Korea, DeLLphi-301 trialThe Center for Cancer Care and Research, St. Louis, USAThoracic Oncology Division, Shizuoka Cancer Center Hospital, Shizuoka, JapanUniversidad Complutense and Ciberonc, Madrid, Spain, CASPIAN trialUniversity of Maryland Cancer CenterVanderbilt University Medical Center, Nashville, IMpower133Westdeutsches Tumorzentrum EssenWest Japan Thoracic Oncology Group 9902Zentralkrankenhaus Gauting, Abteilung Onkologie, DeutschlandProtocols in Revision 72 protocols foundACO II - Doxorubicin 60 / Cyclophosphamide 750 / Vincristine 1.5, Small Cell Lung Carcinoma (PID218 V2.0)Atezolimab 1200 / Carboplatin 5 / Etoposide 100, Small Cell Lung Cancer (PID1341 V1.2)Atezolizumab 1200, Lung Carcinoma, Small Cell, Maintenance (PID1342 V1.0)Carboplatin 300 / Etoposide 100, Lung Carcinoma, Small Cell (PID210 V1.1)Carboplatin 300 / Etoposide 140 / Vincristine 2, Small Cell Lung Carcinoma, Small Cell (PID207 V1.1)Carboplatin 5 / Etoposide 100, Small Cell Lung Carcinoma, Small Cell (PID209 V1.3)Carboplatin 5 / Etoposide 110 / Vincristine 2, Lung Carcinoma, Small Cell (limited disease) (PID1477 V1.0)Carboplatin 5 / Etoposide 140, Lung Carcinoma, Small Cell (PID204 V1.1)Carboplatin 5 / Etoposide 80, Lung Carcinoma, Small Cell (PID208 V1.2)Carboplatin 5 / Etoposide 90 / Vincristine 2, Lung Carcinoma, Small Cell (extensive disease) (PID1476 V1.0)Carboplatin 6 / Etoposide 100 / Radiation, Small Cell Lung Cancer (PID2267 V1.0)Cisplatin 100 / Etoposide 100, Lung Carcinoma, Small Cell (PID201 V1.2)Cisplatin 20 / Etoposide 75 / Ifosfamide 1,2, Small Cell Lung Carcinoma (PID233 V1.2)Cisplatin 25 / Etoposide 100 / Radiation, Small Cell Lung Carcinoma, Small Cell (PID1256 V1.1)Cisplatin 25 / Etoposide 60 / Irinotecan 90, Small Cell Lung Carcinoma (PID741 V1.1)Cisplatin 25 / Etoposide 80, Lung Carcinoma, Small Cell (PID216 V1.1)Cisplatin 30, Tumor, Various Organs (PID2371 V1.0)Cisplatin 60 / Etoposide 120 / Radiation, Small Cell Lung Carcinoma, Small Cell (PID264 V1.2)Cisplatin 60 / Etoposide 120, Lung Carcinoma, Small Cell (PID217 V1.2)Cisplatin 75 / Etoposide (100/200), Small Cell Lung Cancer (PID2558 V1.0)Cisplatin 75 / Etoposide 100 / Radiation, Small Cell Lung Carcinoma, Small Cell (PID1254 V1.1)Cisplatin 75 / Etoposide 100, Small Cell Lung Carcinoma (PID2266 V1.1)Cisplatin 80 / Etoposide 100 / Radiation, Small Cell Lung Carcinoma, Small Cell (PID265 V1.2)Cisplatin 80 / Etoposide 100 / Radiation, Small Cell Lung Cancer, Part A (PID266 V1.2)Cisplatin 80 / Etoposide 100, Lung Carcinoma, Small Cell (PID214 V1.3)Cisplatin 80 / Etoposide 120, Lung Carcinoma, Small Cell (PID211 V1.2)Cisplatin 80 / Etoposide 80, Lung Carcinoma, Small Cell (PID215 V1.2)Cyclophosphamide 1000 / Doxorubicin 45 / Etoposide 50, Small Cell Lung Carcinoma (PID260 V1.0)Cyclophosphamide 1000 / Doxorubicin 50 / Vincristine2, Small Cell Lung Carcinoma, Small Cell (PID224 V1.0)Cyclophosphamide 1000 / Etoposide (50/100) / Vincristine 2, Lung Carcinoma, Small Cell (PID225 V1.0)Cyclophosphamide 2000 / Vincristine 2, Small Cell Lung Carcinoma, Small Cell (PID226 V1.0)Doxorubicin 40 / Lurbinectedin 2, Small Cell Lung Cancer (PID2628 V1.0)Durvalumab 1500 / Carboplatin 5 / Etoposide 100 - Durvalumab 1500 Maintenance, Small Cell Lung Carcinoma (PID1594 V1.0)Durvalumab 1500 / Carboplatin 5 / Etoposide 100, Small Cell Lung Carcinoma (PID1593 V1.2)Durvalumab 1500 / Cisplatin 80 / Etoposide 100, Small Cell Lung Carcinoma (PID1734 V1.1)Durvalumab 1500, Small Cell Lung Cancer (PID2651 V1.0)Epirubicin 50 / Cyclophosphamide 1000 / Vincristine 2, Small Cell Lung Cancer (PID259 V1.1)Etoposide 110 / Paclitaxel 175 / Carboplatin 5, Lung Carcinoma, Small Cell (limited disease) (PID263 V1.1)Etoposide 120 / Ifosfamide 5, Small Cell Lung Carcinoma, Small Cell (PID227 V1.2)Etoposide 50, Small Cell Lung Carcinoma (PID244 V1.0)Etoposide 90 / Paclitaxel 175 / Carboplatin 5, Lung Carcinoma, Small Cell (extensive disease) (PID200 V1.1)Ifosfamide 5 / Carboplatin 300 / Etoposide (120/240) / Vincristine 1, Small Cell Lung Carcinoma (PID258 V1.1)Irinotecan 50 / Carboplatin 5, Lung Carcinoma, Small Cell (PID241 V1.0)Irinotecan 60 / Cisplatin 60, Lung Carcinoma, Small Cell (PID230 V1.2)Irinotecan 60 / Cisplatin 60, Small Cell Lung Cancer, Part B (PID267 V1.2)Irinotecan 65 / Cisplatin 30, Lung Carcinoma, Small Cell (PID229 V1.2)Lurbinectedin 3,2, small cell lung cancer (PID1839 V1.1)Lurbinectedin 3.2, Small Cell Lung Cancer, Maintenance (PID2629 V1.0)Paclitaxel 175 / Cisplatin 80 / Etoposide 80, Small Cell Lung Cancer (PID232 V1.1)Paclitaxel 80 / Carboplatin 2, Small Cell Lung Carcinoma (PID242 V1.2)Paclitaxel 80, Small Cell Lung Carcinoma (PID245 V1.1)Pembrolizumab 200 / Carboplatin 5 / Etoposide 100, Lung Carcinoma, Small Cell (PID630 V1.1)Pembrolizumab 200 / Cisplatin 75 / Etoposide 100, Small Cell Lung Carcinoma, Small Cell (PID610 V1.1)Pembrolizumab 200, Lung Carcinoma, Small Cell, Maintenance (PID631 V1.0)Pembrolizumab 200, Small Cell Lung Carcinoma, Second Line (PID1345 V1.1)Serplulimab 4.5 / Carboplatin 5 / Etoposide 100, Small Cell Lung Cancer, Cycle 1-4 (PID2922 V1.0)Serplulimab 4.5, Small Cell Lung Cancer, Cycle 5+ (PID2923 V1.0)Tarlatamab (1/10), Small Cell Lung Cancer, Cycle 1 (PID2858 V1.0)Tarlatamab 10, Small Cell Lung Cancer, Cycle 2+ (PID2859 V1.0)Thiotepa 15 / Hydrocortisone 30, Tumor, Various Organs (PID2372 V1.0)Tislelizumab 200 / Carboplatin 5 / Etoposide 100, Small Cell Lung Cancer, Cycle 1-4 (PID2915 V1.0)Tislelizumab 200 / Cisplatin 75 / Etoposide 100, Small Cell Lung Cancer, Cycle 1-4 (PID2914 V1.0)Tislelizumab 200, Small Cell Lung Cancer, Cycle 5+ (PID2916 V1.0)Topotecan 0.75 / Carboplatin 5, Lung Carcinoma, Small Cell (PID238 V2.0)Topotecan 1 / Cisplatin 75, Small Cell Lung Carcinoma (PID235 V2.2)Topotecan 1.25 / Carboplatin 5, Lung Carcinoma, Small Cell (PID237 V2.0)Topotecan 1.5 / Cisplatin 75, Lung Carcinoma, Small Cell (PID236 V2.1)Topotecan 1.5, small cell lung cancer (PID203 V2.0)Topotecan 1.7 / Cisplatin 60, Lung Carcinoma, Small Cell (PID228 V1.1)Topotecan 2, Small Cell Lung Carcinoma (Schiller variant) (PID234 V2.0)Topotecan 2,3, Small Cell Lung Cancer (PID231 V1.0)Topotecan 4, Small Cell Lung Carcinoma (PID240 V1.0)
